Back to Results

NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

II/III - A combination of phases: (2) Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied. and (3) Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

Greeley Campus
Harmony Campus
Highlands Ranch Hospital
Medical Center of the Rockies
Memorial Hospital Central
Memorial Hospital North
Poudre Valley Hospital
University of Colorado Hospital

Principal Investigator
Kian Behbakht,  MD

Kian Behbakht, MD

Study ID

Protocol Number: 16-0708

ClinicalTrials.gov: NCT02502266

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers